Incidence of mycosis fungoides in patients with chronic psoriasis vulgaris

Authors

  • Mayra Alejandra Navarro Lambraño Facultad de Medicina y Ciencias de la Salud - Universidad Abierta Interamericana. Author
  • Valeria Vallejo Facultad de Medicina y Ciencias de la Salud - Universidad Abierta Interamericana. Author

DOI:

https://doi.org/10.56294/piii2024340

Keywords:

psoriasis, mycosis fungoides, neoplasia or malignancy, lymphomas, immunosuppressive agents

Abstract

Background: Psoriasis is a chronic dermatosis, characterized by erythematous and scaly plaques, affecting 2 -3% of people worldwide. And on the other hand we have mycosis fungoides, the most common cutaneous T-cell lymphoma, which presents manifestations that vary from erythematous macules to tumors. 
These two pathologies are independent, however, their clinical and pathological similarity has generated erroneous diagnoses. However, literature has marked a possible connection between the two. The relationship between psoriasis and mycosis fungoides, as well as the appearance of mycosis fungoides after systemic treatment for psoriasis, has generated a great enigma and really requires exhaustive study. Material and methods: A systematic review of publications of studies on the incidence of mycosis fungoides in chronic psoriasis vulgaris patients is carried out, and a meta-analysis will be carried out that incorporates all the published information available using the online databases pubmed, google scholar, trip medical database, Embase, prospero International prospective register of systematic reviews 
 Results: The systematic review concluded that 47 cases met the inclusion criteria, that is, patients with a history of long-standing psoriasis vulgaris, of which 38 patients received biological therapy and 32 patients developed mycosis fungoides. 
Conclusion:  The association between mycosis fungoides and long-standing psoriasis vulgaris is a complex issue, mainly due to its difficulty in clinically differentiating both diseases, which often generates an erroneous diagnosis. Likewise, there have been cases of coexistence of both pathologies and the appearance of mycosis fungoides secondary to long-standing treatments for psoriasis vulgaris. A clear association between psoriasis and mycosis fungoides has not yet been established. However, it is possible that this connection is favored by the immunopathology of psoriasis due to the constant activation of the immune system and the presence of Th17 cells, predisposing to the development of mycosis fungoides. However, there are few studies on these topics specifically. It is imperative that more studies be conducted to understand the mechanisms involved, develop and establish more specific management guidelines against therapies for patients with pre-existing risk factors. Some studies have suggested an association between the use of biologic therapies for psoriasis and an increased risk of developing or exacerbating mycosis fungoides in certain patients. However, the evidence is still inconclusive and more research is needed to fully understand this relationship. Concern about the impact of immunological therapies in long-standing psoriasis vulgaris highlights the need for constant monitoring and long-term investigations to better understand the long-term effects of these treatments. The actual incidence and prevalence of the relationship between long-standing psoriasis vulgaris and mycosis fungoides cannot be determined with certainty

References

López Pupo Natacha, Tablada Robinet María Elena, Jacas Portuondo Ana Lucía, Baltazar Green Adelina, González Vázquez Luis Felipe. Factores de riesgo y comorbilidades en pacientes con psoriasis. MEDISAN [Internet]. 2019 Jun [citado 2024 Feb 16]; 23(3): 435-446. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1 029-30192019000300435&lng=es. Epub 28-Jun-2019.

Cruz Camejo Yaniurka, Cáceres Lavernia Haslen Hassiul, Flores Vega Yoanna Ivette, Rodríguez Abascal, Alicia Amelia, Alsina Sarmiento Sofía de la Caridad, Morales López Jorge Luis. Micosis fungoide en estadio tumoral. Presentacion de un caso. Rev haban cienc méd [Internet]. 2011 Dic [citado 2024 Ene 06]; 10(4): 476-485. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1 729-519X2011000400009&lng=es.

Biondo G, Cerroni L, Brunasso AMG, et al. Risk of mycosis fungoides in psoriatic patients: a critical review. J Eur Acad Dermatol Venereol. 2020; 34(6):1186-1195. doi:10.1111/jdv.16160.

Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006; 126(10):2194-2201. doi:10.1038/sj.jid.5700410

Nikolaou V, Marinos L, Moustou E, et al. Psoriasis in patients with mycosis fungoides: a clinicopathological study of 25 patients. J Eur Acad Dermatol Venereol. 2017; 31(11):1848-1852. doi:10.1111/jdv.14365

Diakomopoulos A, Dalamaga M, Papadavid E. Understanding the enigmatic association between mycosis fungoides and psoriasis: Report of two cases and review of the literature. Metabol Open. 2021; 12:100148. Published 2021 Nov 4. doi:10.1016/j.metop.2021.100148

Vaengebjerg S, Skov L, Egeberg A, Loft ND. Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis. JAMA Dermatol. 2020; 156(4):421-429. doi:10.1001/jamadermatol.2020.0024

Roccuzzo, G., Cavallo, F., Avallone, G., Fava, P., Conti, L., Ribero, S., Fierro, M. T., & Quaglino, P. (2022). Guttate psoriasis in a patient with mycosis fungoides in treatment with Brentuximab vedotin: An unreported association. Dermatologic Therapy, 35(4), 1–2. https://doi.org/10.1111/dth.15309

Yoo J, Shah F, Velangi S, Stewart G, Scarisbrick JS. Secukinumab for treatment of psoriasis: does secukinumab precipitate or promote the presentation of cutaneous T-cell lymphoma? Clin Exp Dermatol. 2019; 44(4):414-417. doi:10.1111/ced.13777

Doughty H, Scripture A, Carter JB, et al. Adnexotropic and granulomatous mycosis fungoides following TNF-α inhibitor treatment. J Cutan Pathol. 2023; 50(7):611-616. doi:10.1111/cup.14441

Mohamed, M., Korbi, M., Youssef, M., Moussa, A., Laatiri, A., Belhadjali, H., & Zili, J. (2016). B-cell chronic lymphocytic leukemia followed by mycosis fungoides in a psoriatic patient on long-term methotrexate therapy. Indian Journal of Dermatology, Venereology and Leprology, 83.

Di Lernia, V., Ricci, C., Grenzi, L., Froio, E., & Piana, S. (2009). Folliculotropic mycosis fungoides in a psoriatic patient under methotrexate treatment. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology: JDDG, 7(12), 1068– 1070. https://doi.org/10.1111/j.1610-0387.2009.07153.x

Kołkowski K, Sokołowska-Wojdyło M. Safety and danger of biologic treatments in psoriasis in context of cutaneous T-cell lymphoma (CTCL). Postepy Dermatol Alergol. 2021; 38(6):953-960. doi:10.5114/ada.2021.107553

Fahmy LM, Schreidah CM, Lapolla BA, Magro CM, Geskin LJ. Mycosis fungoides diagnosed after exposure to risankizumab for psoriasis. JAAD Case Rep. 2023; 41:85-89. Published 2023 Sep 27. doi:10.1016/j.jdcr.2023.08.049

Davis MS, Spencer RK, Johnson CE, et al. Risk of Cutaneous T Cell Lymphoma with Psoriasis Biologic Therapies. Dermatol Ther (Heidelb). Published online December 3, 2023. Doi:10.1007/s13555-023-01074-z

Downloads

Published

2024-06-12

How to Cite

1.
Navarro Lambraño MA, Vallejo V. Incidence of mycosis fungoides in patients with chronic psoriasis vulgaris. SCT Proceedings in Interdisciplinary Insights and Innovations [Internet]. 2024 Jun. 12 [cited 2024 Oct. 7];2:340. Available from: https://proceedings.ageditor.ar/index.php/piii/article/view/305